Metagenomi Therapeutics (MGX) Operating Margin (2023 - 2026)
Metagenomi Therapeutics (MGX) reported Operating Margin of 1970.11% for Q1 2026, down 129601.0% year-over-year from N/an in Q1 2025, and down 216.21% quarter-over-quarter from 623.04% in Q4 2025.
Metagenomi Therapeutics (MGX) Operating Margin (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has 4 years of Operating Margin data on file, last reported at 1970.11% in Q1 2026.
- Operating Margin for Q1 2026 came in at 1970.11%, down 129601.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 415.48% (down 22174.0% YoY), and the FY2025 annual result was 380.85%, down 21085.0% from the prior year.
- Operating Margin slipped to 1970.11% in Q1 2026 per MGX's latest filing, from 623.04% in the prior quarter.
- Over five years, Operating Margin peaked at 84.28% in Q2 2024 and troughed at 1970.11% in Q1 2026.
- A 4-year average of 403.12% and a median of 214.51% in 2024 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2024 and 2026: Operating Margin jumped 7416 bps in 2024, then sank 129601 bps in 2026.
- A 4-year view of Operating Margin shows it stood at 162.88% in 2023, then tumbled by 32 bps to 214.51% in 2024, then plunged by 190 bps to 623.04% in 2025, then tumbled by 216 bps to 1970.11% in 2026.
- Business Quant data shows MGX's Operating Margin at 1970.11% in Q1 2026, 623.04% in Q4 2025, and 263.76% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 821,726.73 Bn | 821,726.69 Bn | - | - |
| 2 | Belite Bio | 57,768.00 Bn | 57,768.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,655.88 Bn | 16,655.88 Bn | - | - |
| 4 | Legend Biotech | 3,540.00 Bn | 3,539.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,526.26 Bn | 1,526.24 Bn | - | - |
| 6 | Akari Therapeutics | 1,520.09 Bn | 1,520.09 Bn | - | - |
| 7 | Psyence Biomedical | 223.87 Bn | 223.87 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.47 Bn | 107.23 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.22 Bn | 91.22 Bn | - | - |
| 10 | Metagenomi Therapeutics | 42.84 Mn | 42.84 Mn | - | -1,970.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,970.11% |
| Dec 31, 2025 | -623.04% |
| Sep 30, 2025 | -263.76% |
| Jun 30, 2025 | -246.53% |
| Mar 31, 2025 | -674.10% |
| Dec 31, 2024 | -214.51% |
| Sep 30, 2024 | -194.40% |
| Jun 30, 2024 | -84.28% |
| Mar 31, 2024 | -260.17% |
| Dec 31, 2023 | -162.88% |
| Sep 30, 2023 | -181.15% |
| Jun 30, 2023 | -158.45% |
| Mar 31, 2023 | -207.21% |